nitric oxide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-23. Anything still debated is marked as such rather than presented as settled.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
On December 18, 2018, Kennedy voted against the First Step Act, a criminal justice reform bill that reduced the prison sentences of some federal inmates. He said, "I voted against this bill because the most important goal of the criminal justice system for American families is justice. This bill is backwards. It favors criminals over victims. It forgets that the ultimate goal is justice. We’ve seen what’s happened with so-called criminal justice reform in Louisiana. People are literally getting killed." On October 5, 2018, Kennedy introduced a Small Business Administration Disaster Loan bill to stop the agency from dropping SBA loan limits from $25,000 to $14,000 to ensure businesses have funds to rebuild following natural disasters. The bill passed the Senate with unanimous consent. President Trump signed it into law on November 29, 2018. On November 15, 2018, Kennedy introduced the National Flood Insurance Program Extension Act, a bill that amended the National Flood Insurance Act of 1968 to reauthorize the National Flood Insurance Program until June 1, 2019, to avoid a lapse in the program. The bill passed the Senate with unanimous consent and passed the House with a vote of 315–48. Trump signed the bill into law on December 21, 2018. In 2018, Kennedy worked with Senator Joe Manchin on the Justice Against Corruption on K Street (JACK) Act. The bill was named after Jack Abramoff, a lobbyist who was convicted of fraud, corruption, and conspiracy.
After a slow start in the final's first two events, after which he found himself 7 points behind the leader in seventh place, he proceeded to dominate the rest of the event with five first place finishes in a row in the final five disciplines, winning the title with an event to spare. In the 2006 World's Strongest Man contest, despite starting the final well, he eventually came second to Phil Pfister after the American won the final five events in a row. Pudzianowski regained his title in 2007, winning the final with one event to spare for a record-breaking third time. In so doing, he joined Jon Pall Sigmarsson and Magnus Ver Magnusson as the only men to win the competition four times. During the 2007 competition, however, Pudzianowski said that his target was to become the only person to win the event five times, and he returned to the 2008 World's Strongest Man the following year to try to achieve his goal. Despite a serious calf injury suffered in the Polish Strongman Championship Cup of 2008 and further exacerbated during the WSM qualifying rounds, Pudzianowski still managed to win his heat and qualify for the final. However, it was clear his dominance of previous years was no longer in effect, as he only won one of the first five events in the final, and finished in fifth in two others. Trailing leader Derek Poundstone with two events to go, Pudzianowski managed to win the Plane Pull despite his injured calf to cut the deficit to just 1 point going into the final event.
== Epithelial membrane == The epithelial membrane is composed of epithelium attached to a layer of connective tissue, for example, skin. The mucous membrane is also a composite of connective and epithelial tissues. Sometimes called mucosae, these epithelial membranes line the body cavities and hollow passageways that open to the external environment, and include the digestive, respiratory, excretory, and reproductive tracts. Mucus, produced by the epithelial exocrine glands, covers the epithelial layer. The underlying connective tissue, called the lamina propria (literally “own layer”), help support the fragile epithelial layer. A serous membrane is an epithelial membrane composed of mesodermally derived epithelium called the mesothelium that is supported by connective tissue. These membranes line the coelomic cavities of the body, that is, those cavities that do not open to the outside, and they cover the organs located within those cavities. They are essentially membranous bags, with mesothelium lining the inside and connective tissue on the outside. Serous fluid secreted by the cells of the thin squamous mesothelium lubricates the membrane and reduces abrasion and friction between organs. Serous membranes are identified according locations. Three serous membranes line the thoracic cavity; the two pleura that cover the lungs and the pericardium that covers the heart. A fourth, the peritoneum, is the serous membrane in the abdominal cavity that covers abdominal organs and forms double sheets of mesenteries that suspend many of the digestive organs.
Sources: en.wikipedia.org
== Further reading == Kishi, K.; Okabe, K.; Shimizu, R.; Kubota, Y. (2012). "Fetal Skin Possesses the Ability to Regenerate Completely: Complete Regeneration of Skin". The Keio Journal of Medicine. 61 (4): 101–108. doi:10.2302/kjm.2011-0002-ir. PMID 23324304.
=== Health === In 2019, she was admitted to a local hospital after complaining of severe pain and illness. It was later revealed that she had caught a life-threatening bacterial infection, which was treated immediately. In February 2021, she underwent a removal of her breast implants and discussed her reason for choosing to remove her implants a year later in a YouTube video. In September 2024, Pansino posted an update on social media stating that she had been diagnosed with premenstrual dysphoric disorder (PMDD). She shared that it had been causing disruptions in her life that at times, had caused her to cancel all plans for weeks and that her symptoms had sent her to the emergency room twice. She also mentioned that she was working with a hormone specialist for treatment. In September 2025, Pansino posted an update on Facebook that her symptoms of PMDD were worsening to the point of causing disruptions in her daily life. As part of her post, she stated, "Recently, my own PMDD symptoms have gotten much worse and it has completely disrupted my ability to have a normal life. I am working with professionals to get onto a new treatment plan." She also posted that she was going to take a break from social media to focus on her treatment and that she intended to make an educational video on PMDD. In June 2025, Pansino posted on social media that she had a benign growth removed from her clavicle after finding the growth the previous year and having undergone an inconclusive biopsy.
The independence of Poland had been campaigned for in Russia and in the West by Dmowski and in the West by Ignacy Jan Paderewski. Tsar Nicholas II of Russia, and then the leaders of the February Revolution and the October Revolution of 1917, installed governments who declared in turn their support for Polish independence.[d1] In 1917, France formed the Blue Army (placed under Józef Haller) that comprised about 70,000 Poles by the end of the war, including men captured from German and Austrian units and 20,000 volunteers from the United States. There was also a 30,000-men strong Polish anti-German army in Russia. Dmowski, operating from Paris as head of the Polish National Committee (KNP), became the spokesman for Polish nationalism in the Allied camp. On the initiative of Woodrow Wilson's Fourteen Points, Polish independence was officially endorsed by the Allies in June 1918.[c1] In all, about two million Poles served in the war, counting both sides, and about 400–450,000 died. Much of the fighting on the Eastern Front took place in Poland, and civilian casualties and devastation were high.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.